Can I Take Creatine with Tresiba (Insulin Degludec)?

How Insulin Degludec Works and Why Supplement Interactions Matter

Insulin degludec is an ultra-long-acting basal insulin that forms multi-hexameric chains at the injection site, producing a flat pharmacokinetic profile and a half-life of roughly 25 hours. The FDA label notes a duration of action exceeding 42 hours in most adults, which distinguishes it from insulin glargine U-300 and detemir. Because the insulin remains active for so long, any factor that shifts glucose metabolism, even modestly, can have lasting effects on blood sugar control.

Why Supplement Safety Reviews Are Different for Insulin Users

People using basal insulin carry a baseline hypoglycemia risk that non-insulin users do not. A supplement that is benign in a healthy athlete may tip glucose regulation in someone whose basal rate is already set near the lower edge of euglycemia. That is why the ADA's Standards of Care in Diabetes, 2024 explicitly recommends that clinicians review all over-the-counter supplements and ergogenic aids at each visit for patients on insulin therapy. ADA Standards 2024, Section 5.

Creatine is one of the most widely used sports supplements worldwide. An estimated 20 to 30% of competitive athletes report regular creatine use, based on survey data compiled in Maughan et al., 2018 (Br J Sports Med). Given that adults with type 1 and type 2 diabetes are increasingly active in recreational sport and resistance training, the overlap between creatine users and Tresiba users is clinically meaningful.

The Pharmacokinetic Question

No published pharmacokinetic study has directly examined creatine co-administration with insulin degludec. Creatine is not metabolized by cytochrome P450 enzymes and does not bind plasma proteins in a way that would displace insulin from its carrier proteins (insulin itself circulates mostly unbound). PubMed: creatine metabolism review, Wyss & Kaddurah-Daouk 2000. There is therefore no pharmacokinetic basis for a direct drug-supplement interaction.

The Creatinine Problem: Why This Matters More Than Most Interactions

Creatine supplementation reliably raises serum creatinine. This is not a sign of kidney damage, it reflects the fact that creatine is metabolized to creatinine in muscle tissue, and higher creatine stores produce more creatinine as a byproduct. A 2003 randomized controlled trial by Poortmans and Francaux (N=18) found that 5 g/day of creatine for 5 days raised serum creatinine by approximately 0.2 to 0.3 mg/dL without any change in cystatin C or inulin-clearance GFR. Poortmans & Francaux, Nephrol Dial Transplant 2003.

Why Creatinine Elevation Is a Bigger Deal in Diabetes

Diabetes is the leading cause of chronic kidney disease in the United States, accounting for 38% of all new end-stage renal disease cases per USRDS 2022 Annual Data Report (NIH). Because CKD progression affects insulin clearance, drug dosing, and hypoglycemia risk, clinicians rely heavily on eGFR trends to guide dose adjustments and medication safety. If creatine artificially inflates serum creatinine by 0.2 to 0.3 mg/dL, the CKD-EPI equation may produce an eGFR reading that is 5 to 10 mL/min/1.73m² lower than true GFR, enough to shift a patient from CKD stage G2 to G3a on paper.

A 2022 systematic review in the Clinical Journal of the American Society of Nephrology confirmed that creatinine-based GFR equations consistently underestimate true GFR in creatine users. Ostojic & Forbes, CJASN 2022. The practical implication: a Tresiba user who starts creatine may appear to have deteriorating kidney function when their kidneys are actually stable.

How to Monitor Kidney Function If You Use Both

Cystatin C is filtered freely by the glomerulus and is not affected by muscle mass or creatine metabolism. Rule & Lieske, CJASN 2018 recommend cystatin C-based eGFR (CKD-EPI Cys) as the preferred measure when creatinine results seem inconsistent with clinical context. For Tresiba users adding creatine, a baseline cystatin C reading before starting the supplement, and a repeat at 3 months, gives clinicians a creatine-unaffected reference point.

KDIGO 2022 guidelines specify that eGFR should be measured at least annually in all people with diabetes, and more frequently (every 3 to 6 months) once eGFR drops below 60 mL/min/1.73m². KDIGO 2022 CKD Guideline. Adding creatine does not change this schedule but does change which lab marker is most trustworthy.

Does Creatine Affect Blood Glucose or Insulin Sensitivity?

This is where the pharmacodynamic picture becomes genuinely interesting. Several studies have examined whether creatine modifies glucose metabolism, and the results lean mildly favorable.

Evidence That Creatine May Improve Glucose Metabolism

A 12-week RCT by Gualano et al. (N=25, type 2 diabetes) found that creatine supplementation at 5 g/day combined with aerobic exercise training produced a significantly greater reduction in HbA1c compared to placebo plus exercise (HbA1c reduction: 1.1% vs. 0.3%, P<0.05). Gualano et al., Diabetes Care 2011. The proposed mechanism involves upregulation of GLUT-4 translocation in skeletal muscle via creatine-driven ATP resynthesis, which may enhance insulin-stimulated glucose uptake independently of insulin signaling.

A separate mechanistic study by Op't Eijnde et al. Demonstrated that creatine supplementation increased muscle GLUT-4 protein content by approximately 40% in healthy volunteers. Op't Eijnde et al., Diabetes 2001. If this effect holds in insulin-treated patients, it could theoretically amplify the glucose-lowering effect of Tresiba during and after resistance training sessions.

The Exercise-Context Hypoglycemia Risk

This is the practical consequence that most patients and clinicians overlook. Creatine itself does not lower blood glucose. Exercise does. Creatine improves training performance, which can intensify workouts, which increases muscle glucose uptake, which can produce post-exercise hypoglycemia in a person whose basal insulin dose was set for a lower activity level.

A 2017 position statement by the American Diabetes Association on physical activity notes that resistance exercise can cause delayed hypoglycemia up to 24 hours after the session. Colberg et al., Diabetes Care 2016. Because Tresiba has an action duration exceeding 42 hours, the flat peakless profile actually offers some protection compared to NPH or glargine, but it does not eliminate the risk. Patients who start creatine and consequently train harder should monitor glucose more frequently for the first 2 to 4 weeks and discuss basal dose adjustment with their prescriber.

What the Evidence Does Not Show

No published trial has demonstrated that creatine monohydrate directly causes hypoglycemia in insulin-naive or insulin-treated participants. The International Society of Sports Nutrition's 2017 position stand, authored by Kreider et al. And covering data from over 500 studies, found no clinically significant adverse effects on glucose regulation at doses of 3 to 5 g/day. Kreider et al., JISSN 2017.

Renal Safety of Creatine in Diabetic Kidney Disease

Concerns about creatine and kidney health have circulated for decades, largely driven by case reports that did not adequately control for confounders. The current evidence base is more reassuring.

Long-Term Safety Data

A 2-year observational study by Poortmans et al. Found no decline in renal function markers (creatinine clearance, albumin excretion) in athletes using creatine at 10 g/day. Poortmans & Francaux, Sports Med 2000. A Cochrane-registered systematic review by Jäger et al. Similarly found no evidence of nephrotoxicity from creatine supplementation at standard doses in people without pre-existing kidney disease. Jäger et al., JISSN 2011.

The critical caveat is "without pre-existing kidney disease." Patients with CKD stage G3b or worse (eGFR <45 mL/min/1.73m²) have not been studied in long-term creatine trials. The KDIGO 2022 guidelines advise caution with any supplement that increases metabolic load on impaired kidneys. KDIGO 2022, Kidney Int Suppl.

Practical CKD Thresholds for Creatine Use in Tresiba Patients

The HealthRX medical team applies the following creatine safety framework for patients on insulin degludec:

| eGFR (CKD-EPI, mL/min/1.73m²) | Creatine Recommendation | |---|---| | >60 (G1, G2) | Generally acceptable; obtain baseline cystatin C before starting | | 45 to 59 (G3a) | Use with caution; confirm true GFR with cystatin C; limit to 3 g/day | | 30 to 44 (G3b) | Avoid until nephrology clearance; creatinine-based monitoring unreliable | | <30 (G4, G5) | Do not use without explicit nephrology approval |

This framework is based on published creatine pharmacology, KDIGO 2022 CKD staging, and the recognized limitation of creatinine-based GFR equations in creatine users. It has not been validated in a prospective trial and should be applied alongside individualized clinical judgment.

Practical Guidance for People Already Using Both

If a patient is already taking creatine and Tresiba, the priority is not to panic about an acute interaction that does not exist pharmacokinetically. The priorities are monitoring accuracy and exercise-related glucose safety.

Step-by-Step Monitoring Plan

First, order a cystatin C-based eGFR at the next lab visit to establish a creatine-adjusted baseline. Serum creatinine alone may read falsely elevated by 0.2 to 0.3 mg/dL. Poortmans & Francaux 2003.

Second, ask the patient about recent changes to training volume or intensity. Creatine's performance-enhancing effect (average power output increase of 5 to 15% documented in meta-analysis by Lanhers et al.) can meaningfully increase glucose consumption during exercise. Lanhers et al., Eur J Sport Sci 2017.

Third, review the Tresiba dose in the context of updated activity levels. The ADA's 2024 Standards recommend that insulin doses be adjusted proactively when exercise frequency or intensity changes by more than 20%. ADA Standards 2024, Section 16.

Timing Considerations

There is no pharmacokinetic reason to separate creatine ingestion from the Tresiba injection by a specific window. Tresiba is administered subcutaneously and does not interact with orally ingested creatine in the GI tract or during absorption. Patients can take creatine at whatever time fits their routine, post-workout is a common and reasonable choice given some evidence of enhanced uptake in the post-exercise window. Candow et al., Nutrients 2021.

What to Tell Your Prescriber

Patients should disclose creatine use at every diabetes review visit. The disclosure allows the prescriber to flag the creatinine interpretation issue before it causes a spurious CKD escalation and, potentially more important, before it triggers unnecessary referrals or medication changes based on a lab artifact.

The ADA's 2024 Standards of Care state directly: "Clinicians should routinely ask about use of complementary and alternative products, including dietary supplements, as these may interact with diabetes medications or affect glycemic control." ADA Standards 2024, Section 5.

Creatine Loading vs. Maintenance Dosing: Does the Dose Change the Risk?

Some protocols begin with a loading phase of 20 g/day for 5 to 7 days before dropping to 3 to 5 g/day maintenance. The loading phase produces a sharper and larger rise in serum creatinine. A study by Francaux & Poortmans (1999, N=20) found that loading at 21 g/day for 5 days raised serum creatinine by up to 0.5 mg/dL, roughly double the elevation seen at maintenance dosing. Francaux & Poortmans, Int J Sports Med 1999.

Recommendation on Loading for Tresiba Users

For patients with diabetes on Tresiba, the HealthRX medical team suggests skipping the loading phase and going directly to 3 to 5 g/day maintenance dosing. The performance difference between loading and no-loading is detectable at 4 weeks but negligible at 28 days, per the ISSN position stand. Kreider et al., JISSN 2017. Avoiding the loading phase minimizes the creatinine spike and keeps renal monitoring more straightforward during the first month.

Creatine Form: Monohydrate vs. Alternatives

Creatine monohydrate is the only form with a substantial published evidence base. Buffered creatine (Kre-Alkalyn), creatine ethyl ester, and creatine HCl have not been studied in populations with diabetes, and none has demonstrated superiority to monohydrate in RCTs. Jäger et al., JISSN 2011. Stick to monohydrate at 3 to 5 g/day.

Hydration, Osmolarity, and Insulin Absorption

Creatine draws water into muscle cells (intracellular fluid shift of approximately 1 L during loading). This does not significantly alter plasma osmolarity in healthy adults, but it does raise total body water. Subcutaneous insulin absorption from Tresiba's injection site depends on local blood flow and tissue hydration, not systemic osmolarity, so this fluid shift is unlikely to affect insulin pharmacokinetics in any clinically meaningful way. Pharmaceutical review: insulin absorption factors, Heinemann, Diabetes Technol Ther 2020.

Adequate hydration (at least 35 mL/kg/day) remains a general recommendation for creatine users and is independently beneficial for people with diabetic kidney disease. KDIGO 2022.